• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利钠肽和可溶性 ST2 提高超声心动图诊断左心室充盈压升高的能力。

Natriuretic peptides and soluble ST2 improves echocardiographic diagnosis of elevated left ventricular filling pressures.

机构信息

Emergency Institute for Cardiovascular Diseases and Transplantation Târgu Mureş, Târgu Mureş, Romania.

George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Gheorghe Marinescu Street, No. 38, Târgu Mureş, Romania.

出版信息

Sci Rep. 2024 Sep 27;14(1):22171. doi: 10.1038/s41598-024-73349-0.

DOI:10.1038/s41598-024-73349-0
PMID:39333652
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11436802/
Abstract

Elevated filling pressure of the left ventricle (LV) defines diastolic dysfunction. The gold standard for diagnosis is represented by the measurement of LV end-diastolic pressure (LVEDP) during cardiac catheterization, but it has the disadvantage of being an invasive procedure. This study aimed to investigate the correlation between LVEDP and cardiac serum biomarkers such as natriuretic peptides (mid-regional pro-atrial natriuretic peptide [MR-proANP], B-type natriuretic peptide [BNP], and N-terminal prohormone BNP [NT-proBNP]), soluble ST2 (sST2), galectin-3 and mid-regional pro-adrenomedullin (MR-proAMD). Consecutive patients hospitalized in a tertiary center and undergoing left cardiac catheterization were included in the study. Diastolic dysfunction was considered present if the end-expiratory LVEDP was ≥ 15 mmHg. Cardiac biomarkers were determined from pre-procedural peripheral venous blood samples. A total of 110 patients were included, of whom 76 (69.0%) were males, with a median age of 65 (55-71) years. Median LVEDP was 13.5 (8-19) mmHg and diastolic dysfunction was present in 50 (45.4%) of the patients. LVEDP correlated with BNP (p < 0.0001, r = 0.39 [0.20-0.53]), NT-proBNP (p < 0.0001, r = 0.40 [0.22-0.55]), MR-proANP (p = 0.001, r = 0.30 [0.11-0.46]), sST2 (p < 0.0001, r = 0.47 [0.30-0.60]), but not with MR-proAMD (p = 0.77) or galectin-3 (p = 0.76). In the final stepwise multivariable binary logistic regression model, diastolic dysfunction was predicted by NT-proBNP, mitral average E/e', sST2, atrial fibrillation, and left atrium reservoir strain. BNP, NT-proBNP, MR-proANP, and sST2 had predictive value for diastolic dysfunction. In contrast, galectin-3 and MR-proAMD were not associated with increased filling pressures. Furthermore, NT-proBNP and sST2 significantly improved diastolic dysfunction prediction in the final multivariable model.

摘要

左心室充盈压升高定义为舒张功能障碍。舒张功能障碍的诊断金标准是在心脏导管检查期间测量左心室舒张末期压力(LVEDP),但它有一个缺点,就是属于有创性操作。本研究旨在探讨 LVEDP 与心脏血清生物标志物(如利钠肽(中段心房利钠肽 [MR-proANP]、B 型利钠肽 [BNP] 和 N 端脑钠肽前体 [NT-proBNP])、可溶性 ST2(sST2)、半乳糖凝集素-3 和中段肾上腺髓质原肽 [MR-proAMD])之间的相关性。本研究纳入了在一家三级中心住院并接受左心导管检查的连续患者。如果呼气末 LVEDP≥15mmHg,则认为存在舒张功能障碍。心脏生物标志物是从术前外周静脉血样中确定的。共有 110 名患者入选,其中 76 名(69.0%)为男性,中位年龄为 65(55-71)岁。中位 LVEDP 为 13.5(8-19)mmHg,50 名(45.4%)患者存在舒张功能障碍。LVEDP 与 BNP(p<0.0001,r=0.39 [0.20-0.53])、NT-proBNP(p<0.0001,r=0.40 [0.22-0.55])、MR-proANP(p=0.001,r=0.30 [0.11-0.46])、sST2(p<0.0001,r=0.47 [0.30-0.60])相关,但与 MR-proAMD(p=0.77)或半乳糖凝集素-3(p=0.76)不相关。在最终逐步多元二分类逻辑回归模型中,舒张功能障碍由 NT-proBNP、二尖瓣平均 E/e'、sST2、心房颤动和左心房储备应变预测。BNP、NT-proBNP、MR-proANP 和 sST2 对舒张功能障碍具有预测价值。相比之下,半乳糖凝集素-3 和 MR-proAMD 与升高的充盈压无关。此外,NT-proBNP 和 sST2 显著提高了最终多元模型中舒张功能障碍的预测能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2697/11436802/ce1d1704a7f0/41598_2024_73349_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2697/11436802/c0b738f089a9/41598_2024_73349_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2697/11436802/15d23730f2fd/41598_2024_73349_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2697/11436802/ce1d1704a7f0/41598_2024_73349_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2697/11436802/c0b738f089a9/41598_2024_73349_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2697/11436802/15d23730f2fd/41598_2024_73349_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2697/11436802/ce1d1704a7f0/41598_2024_73349_Fig3_HTML.jpg

相似文献

1
Natriuretic peptides and soluble ST2 improves echocardiographic diagnosis of elevated left ventricular filling pressures.利钠肽和可溶性 ST2 提高超声心动图诊断左心室充盈压升高的能力。
Sci Rep. 2024 Sep 27;14(1):22171. doi: 10.1038/s41598-024-73349-0.
2
The role of N terminal pro-brain natriuretic peptide in the evaluation of left ventricular diastolic dysfunction: correlation with echocardiographic indexes in hypertensive patients.N末端脑钠肽前体在评估左心室舒张功能障碍中的作用:与高血压患者超声心动图指标的相关性
Int J Cardiovasc Imaging. 2008 Mar;24(3):253-9. doi: 10.1007/s10554-007-9256-2. Epub 2007 Aug 9.
3
Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in beta-thalassemia major.B 型利钠肽在检测β-地中海贫血症患者隐匿性左心室舒张功能障碍中的预测价值。
Am Heart J. 2010 Jan;159(1):68-74. doi: 10.1016/j.ahj.2009.10.025.
4
Association of Diastolic Dysfunction with N-terminal Pro-B-type Natriuretic Peptide Level in Heart Failure Patients with Preserved Ejection Fraction.射血分数保留的心力衰竭患者舒张功能障碍与N末端B型利钠肽原水平的关联
Mymensingh Med J. 2019 Apr;28(2):333-346.
5
Differential Associations of A-/B-Type Natriuretic Peptides With Cardiac Structure, Function, and Prognosis in Heart Failure.A 型和 B 型利钠肽与心力衰竭患者心脏结构、功能和预后的相关性差异。
JACC Heart Fail. 2024 Mar;12(3):461-474. doi: 10.1016/j.jchf.2023.09.011. Epub 2023 Oct 25.
6
Can pro-brain natriuretic peptide be used as a noninvasive predictor of elevated left ventricular diastolic pressures in patients with normal systolic function?对于收缩功能正常的患者,脑钠肽前体能否用作左心室舒张压升高的非侵入性预测指标?
Am Heart J. 2005 Dec;150(6):1213-9. doi: 10.1016/j.ahj.2005.01.014.
7
B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures.尽管左心室舒张末期压力较高,但肥胖患者的B型利钠肽和N末端B型利钠肽原水平仍较低。
Am Heart J. 2006 Dec;152(6):1071-6. doi: 10.1016/j.ahj.2006.07.010.
8
Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction.普通人群中的氨基末端前B型利钠肽和B型利钠肽:左心室功能障碍的决定因素及检测
J Am Coll Cardiol. 2006 Jan 17;47(2):345-53. doi: 10.1016/j.jacc.2005.09.025. Epub 2006 Jan 4.
9
Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers.利钠肽作为轻度左心室功能障碍的标志物:检测方法对标志物诊断性能的影响。
Clin Chem. 2004 Jul;50(7):1174-83. doi: 10.1373/clinchem.2003.028316. Epub 2004 May 13.
10
Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction.N末端前脑钠肽、脑钠肽和N末端前心钠素在诊断左心室功能障碍中的直接比较
Clin Chim Acta. 2001 Aug 20;310(2):193-7. doi: 10.1016/s0009-8981(01)00578-2.

引用本文的文献

1
The Latest Advances in Omics Technology for Assessing Tissue Damage: Implications for the Study of Sudden Cardiac Death.用于评估组织损伤的组学技术最新进展:对心脏性猝死研究的启示
Int J Mol Sci. 2025 Jul 16;26(14):6818. doi: 10.3390/ijms26146818.
2
Prognostic value of carbohydrate antigen 125 combined with N-terminal pro B-type natriuretic peptide in patients with acute heart failure: a prospective cohort study in Vietnam.糖类抗原125联合N末端B型利钠肽原对急性心力衰竭患者的预后价值:越南的一项前瞻性队列研究
BMC Cardiovasc Disord. 2025 Jul 18;25(1):523. doi: 10.1186/s12872-025-04994-0.
3
Contemporary Perspectives on Congestion in Heart Failure: Bridging Classic Signs with Evolving Diagnostic and Therapeutic Strategies.

本文引用的文献

1
Evaluation of clinical prediction models (part 1): from development to external validation.临床预测模型的评估(第 1 部分):从建立到外部验证。
BMJ. 2024 Jan 8;384:e074819. doi: 10.1136/bmj-2023-074819.
2
Left Atrial Strain for Assessment of Left Ventricular Diastolic Function: Focus on Populations With Normal LVEF.左心房应变评估左心室舒张功能:关注射血分数正常人群。
JACC Cardiovasc Imaging. 2023 May;16(5):691-707. doi: 10.1016/j.jcmg.2022.10.011. Epub 2023 Jan 11.
3
New insights into the potential utility of the left atrial function analysis in heart failure with preserved ejection fraction diagnosis.
心力衰竭中充血的当代观点:将经典体征与不断发展的诊断和治疗策略相联系
Diagnostics (Basel). 2025 Apr 24;15(9):1083. doi: 10.3390/diagnostics15091083.
4
Natriuretic Peptides and Soluble ST2 Improve Echocardiographic and Invasive Long-Term Survival Prediction in Patients Evaluated for Diastolic Dysfunction.利钠肽和可溶性ST2改善舒张功能障碍评估患者的超声心动图和有创长期生存预测。
Int J Mol Sci. 2025 Apr 14;26(8):3713. doi: 10.3390/ijms26083713.
5
The Role of Antigen Carbohydrate 125 in Modulating Soluble ST2: Prognostic-Related Effects in Acute Heart Failure.抗原碳水化合物125在调节可溶性ST2中的作用:对急性心力衰竭的预后相关影响
Biomolecules. 2025 Apr 18;15(4):602. doi: 10.3390/biom15040602.
6
Cardiovascular Biomarkers: Tools for Precision Diagnosis and Prognosis.心血管生物标志物:精准诊断与预后的工具
Int J Mol Sci. 2025 Mar 30;26(7):3218. doi: 10.3390/ijms26073218.
7
Prediction of myocardial ischemia-reperfusion injury post-PCI: role of sST2 levels in STEMI patients.经皮冠状动脉介入治疗后心肌缺血再灌注损伤的预测:可溶性ST2水平在ST段抬高型心肌梗死患者中的作用
BMC Cardiovasc Disord. 2025 Apr 11;25(1):280. doi: 10.1186/s12872-025-04708-6.
8
Serum CA125: a prognostic biomarker for mortality in chronic heart failure.血清CA125:慢性心力衰竭死亡率的预后生物标志物。
BMC Cardiovasc Disord. 2025 Mar 27;25(1):227. doi: 10.1186/s12872-025-04685-w.
9
Transition to Advanced Heart Failure: From Identification to Improving Prognosis.向晚期心力衰竭的转变:从识别到改善预后
J Cardiovasc Dev Dis. 2025 Mar 17;12(3):104. doi: 10.3390/jcdd12030104.
10
Soluble suppression of tumorigenicity 2 associated with left ventricular thrombosis in patients with ST-segment elevation myocardial infarction.可溶性致瘤性抑制因子2与ST段抬高型心肌梗死患者左心室血栓形成有关。
BMC Cardiovasc Disord. 2025 Mar 20;25(1):204. doi: 10.1186/s12872-025-04667-y.
左心房功能分析在射血分数保留心力衰竭诊断中的潜在应用的新见解。
PLoS One. 2022 May 4;17(5):e0267962. doi: 10.1371/journal.pone.0267962. eCollection 2022.
4
Validation of the 2016 ASE/EACVI Guideline for Diastolic Dysfunction in Patients With Unexplained Dyspnea and a Preserved Left Ventricular Ejection Fraction.2016 年 ASE/EACVI 指南在不明原因呼吸困难和左心室射血分数正常患者舒张功能障碍中的验证。
J Am Heart Assoc. 2021 Sep 21;10(18):e021165. doi: 10.1161/JAHA.121.021165. Epub 2021 Sep 3.
5
A multicenter prospective randomized controlled trial of cardiac resynchronization therapy guided by invasive dP/dt.一项由有创dP/dt指导的心脏再同步治疗的多中心前瞻性随机对照试验。
Heart Rhythm O2. 2021 Jan 22;2(1):19-27. doi: 10.1016/j.hroo.2021.01.005. eCollection 2021 Feb.
6
Biomarkers for the diagnosis and management of heart failure.心力衰竭的诊断和管理生物标志物。
Heart Fail Rev. 2022 Mar;27(2):625-643. doi: 10.1007/s10741-021-10105-w. Epub 2021 Apr 14.
7
The 2016 Diastolic Function Guideline: Is it Already Time to Revisit or Revise Them?《2016年舒张功能指南:现在是否已到重新审视或修订之时?》
JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 2):327-335. doi: 10.1016/j.jcmg.2019.12.004.
8
Continual measurement of arterial dP/dt enables minimally invasive monitoring of left ventricular contractility in patients with acute heart failure.持续测量动脉 dp/dt 可实现对急性心力衰竭患者左心室收缩力的微创监测。
Crit Care. 2019 Nov 21;23(1):364. doi: 10.1186/s13054-019-2654-8.
9
Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week.心力衰竭中 sST2 的临床和预后意义:JACC 本周综述专题。
J Am Coll Cardiol. 2019 Oct 29;74(17):2193-2203. doi: 10.1016/j.jacc.2019.08.1039.
10
Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study.心肌梗死后半乳糖凝集素-3 水平与结局:一项基于人群的研究。
J Am Coll Cardiol. 2019 May 14;73(18):2286-2295. doi: 10.1016/j.jacc.2019.02.046.